SB2 Approval Status
- FDA approved: No
- Brand name: SB2
- Generic name: infliximab
- Company: Samsung Bioepis Co., Ltd.
- Treatment for: Crohn's Disease, Maintenance, Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Plaque Psoriasis
SB2 (infliximab) is an investigational biosimilar alternative to Remicade in development for the treatment of certain serious inflammatory diseases.
Development Status and FDA Approval Process for SB2
|May 23, 2016||Merck Announces FDA Accepts Samsung Bioepis’ BLA for SB2 (infliximab), an Investigational Biosimilar of Remicade|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.